Can a Drug-Vaccine combo outsmart High-Risk CLL?
NCT ID NCT01351896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. The study includes 49 participants and aims to see if the treatment improves antibody responses against infections and shrinks cancer. It is not a cure, but a way to better control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide (a drug that blocks blood flow to cancer and stimulates the immune system) plus a vaccine
- What this could lead to
- If successful, this combination could help control early-stage CLL/SLL by strengthening the immune system's ability to fight cancer cells.
- What could go wrong
- This is a small, early-phase trial (49 participants) with no control group, so results may not apply broadly. Lenalidomide can cause side effects like low blood counts and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?